| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3386f5906dc1bdc9c934203594712c66 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 |
| filingDate |
2004-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b7c96ce2258b72f2d878b09ce939c4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_501c5be30da90b0419dced8df6baef36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9df43eceb7fd8c0a573d128b12f46f4d |
| publicationDate |
2005-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2005130972-A1 |
| titleOfInvention |
Hydroxy piperidine derivatives to treat gaucher disease |
| abstract |
The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10925874-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020006269-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020006296-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012154967-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020023390-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8940766-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102625661-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3552664-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013112706-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010233188-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011065661-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7842470-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9974789-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102625661-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9353117-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010260740-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010118283-A1 |
| priorityDate |
2003-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |